(Q50686384)

17 March 2018

title

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life (English)

1 reference

17 March 2018

1 reference

1 reference

17 March 2018

Dennis P West

0 references

Smita S Joshi

1 reference

17 March 2018

Sara Ortiz

1 reference

17 March 2018

Joslyn N Witherspoon

1 reference

17 March 2018

Alfred Rademaker

1 reference

17 March 2018

Roger Anderson

1 reference

17 March 2018

Sara E Rosenbaum

1 reference

17 March 2018

language of work or name

English

0 references

publication date

1 August 2010

1 reference

17 March 2018

published in

Cancer

1 reference

17 March 2018

volume

116

1 reference

17 March 2018

issue

1 reference

17 March 2018

page(s)

3916-3923

1 reference

17 March 2018

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Measurement properties of skindex-16: A brief quality-of-life measure for patients with skin diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

The psychosocial impact of cancer on older versus younger patients and their families

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Quality of life among younger women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25090

7 January 2021

Identifiers

DOI

10.1002/CNCR.25090

1 reference

17 March 2018

1 reference

17 March 2018